dca

CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC).. CL2A-SN-38 is composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a noncleavable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. .

DCAF1 Ligand 1 (compound I-653) serves as the target protein ligand for PROTA CBRD4-DCAF1 degrader-1, exhibiting a DC50 value of 10~100 nM.

PROTACBRD4-DCAF1 degrader-1 (I-907) is a PROTAC degrader targeting BRD4-DCAF1, exhibiting a DC50 range of 10~100 nM.

DCAF11 ligand 1 acts as a ligand for the E3 ubiquitin ligase DCAF11, and it is used in the synthesis of the PROTAC degrader FF2039.

DCAF15 ligand-1 (compound 9) is a ligand for the E3 ligase DCAF15, suitable for synthesizing PROTACs such as IBG1.

DCAF1 Binder 1 selectively targets the CRL4 DCAF1 E3 ligase complex as a ligand, playing a role in targeted protein degradation (TPD) [1].

DCAF1 Binder 2, an E3 ligase ligand, is implicated in BRD9, kinase, and selective Bruton's tyrosine kinase (BTK) degradation.